Effect of food on oral paclitaxel with encequidar for advanced solid tumors
Part of Cancer, Skin clinical trials.
This trial tests how food affects the absorption of an oral form of paclitaxel (a chemotherapy drug) when taken with another drug called encequidar. It's for people with advanced solid tumors who have limited treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic breast, gastric, lung, or ovarian cancer, or another solid tumor that has spread and standard treatments are not working or not suitable.
- You are able to fast (no food) for 10 hours before and 4 hours after taking the study drugs.
- Your blood counts and liver and kidney function are within acceptable levels.
- You have not had major surgery on your stomach or intestines, and you do not have a condition that affects how you absorb oral medications.
- You are not taking certain medications that could interfere with the study drugs (like strong CYP3A4 inhibitors or inducers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new oral (pill) form of the chemotherapy drug paclitaxel with the standard intravenous (IV) version for people with HER2-negative metastatic breast cancer. The oral form is combined with another drug to help the body absorb more of the chemotherapy, which may make it easier and more convenient while being just as effective.
This study tests a combination of two medications, entinostat and an oral form of paclitaxel, for people with advanced breast cancer that is hormone receptor positive and HER2-negative. If you've already tried several treatments, this might be a new option to help slow the cancer's growth.
This trial tests a combination of an oral chemotherapy drug (paclitaxel) and radiation therapy for people with advanced esophageal cancer that cannot be removed by surgery. It may be an option if you are 70 or older or cannot tolerate IV chemotherapy and have trouble swallowing.
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
This trial tests an oral form of a common chemo drug, paclitaxel, given before surgery for triple-negative breast cancer. It aims to find the best dose and see how well it shrinks tumors.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.